Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19200332 | 0.86 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3CHRM1DRD3 | |
| SCHEMBL16269909 | 0.82 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3CHRM1DRD3 | |
| SCHEMBL12473621 | 0.82 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3CHRM1DRD3 | |
| SCHEMBL17086550 | 0.81 | BCL2A1 (0.49) | SLC6A2SLC6A4SLC6A3CHRM1ALDH1A1 | |
| SCHEMBL21254366 | 0.81 | BCL2A1 (0.49) | SLC6A2SLC6A4SLC6A3CHRM1ALDH1A1 | |
| SCHEMBL21949437 | 0.81 | SLC6A2 (0.36) | KDM4ESLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL20385344 | 0.81 | GAA (0.39) | IDO1CYP2D6TSHRCYP2C19ALDH1A1 | |
| SCHEMBL18239294 | 0.81 | GAA (0.39) | IDO1CYP2D6TSHRCYP2C19ALDH1A1 | |
| SCHEMBL16024187 | 0.79 | CHRM2 (0.47) | KDM4ESLC6A2SLC6A4SLC6A3CHRM1 | |
| SCHEMBL8309312 | 0.78 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3294739-B1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2019-07-31 | — | — | EP | disclosed |
| US-9725449-B2 | Tricyclic compounds as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-08 | — | — | US | disclosed |
| WO-2016183118-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-17 | — | — | WO | disclosed |
| US-20160333013-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333013-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | MCL1, TP53, TOP2A | KDM4E 1736/4885ACHE 1747/4885SLC6A2 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.